AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...

Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie (ABBV) to $221 from $212 and keeps a Buy rating on the shares.

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (e ...

Also, the MassMutual Foundation committed $25 million to expand the reach of nonprofit community development financial institutions, and the Moody Foundation gave $25 million for neuroscience research ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell ...